What Tango Therapeutics, Inc. told the SEC could break it.

Tango's sole API supplier is located in China (a WuXi AppTec affiliate), exposing it to U.S. tariffs on Chinese imports of API/drug product and to the proposed BIOSECURE Act, which could materially restrict its ability to do business with WuXi AppTec.

“on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China (we obtain certain drug product and API from vendors in China and our sole supplier of API is located in China).”

Tango's API for all product candidates is supplied by a single supplier (an affiliate of WuXi AppTec) and its drug product by two manufacturers; these are its sole sources of supply, and the loss of any could significantly harm clinical development.

“The third parties upon whom we rely for the supply of the active pharmaceutical ingredients and drug product to be used in our product candidates are our sole sources of supply, and the loss of any of these suppliers could significantly harm our business. The API we use and that we may continue to use in all of our product candidates is supplied to us from one supplier.”

Tango has generated no product revenue, had a $603.2M accumulated deficit as of December 31, 2025, and is funded primarily by equity financings; the truncation of its Gilead collaboration removed a key non-dilutive funding source, increasing reliance on capital raises.

“As of December 31, 2025, we had an accumulated deficit of $603.2 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.”